MedTrace Logo

Safety Study of the VEGA UV-A System to Treat Ectasia

NCT01398839 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2022-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL) when used to treat ectasia.

Conditions

  • Ectasia

Interventions

DEVICE

VEGA UV-A Illumination System

Only subjects assigned to the treatment group will receive treatment with the UV Light

DRUG

Riboflavin

Both treatment and sham groups will receive riboflavin

Sponsors & Collaborators

  • Topcon Medical Systems, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01398839 on ClinicalTrials.gov